Stay updated with breaking news from Eric Easom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
License enables advancement of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical studies well underway in
License enables advancement of AN2-502998 , a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical studies well underway in...
Key Insights The considerable ownership by individual investors in AN2 Therapeutics indicates that they collectively...
Grant from Bill & Melinda Gates Foundation ...
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries as...